Featured Research

from universities, journals, and other organizations

Confused about prostate cancer screening? Mayo clinic expert helps explain the latest

Date:
June 13, 2012
Source:
Mayo Clinic
Summary:
Urologists recommend a personalized approach to determining whether or not a patient should consider PSA screening for prostate cancer.

There is a lot of conflicting advice about prostate cancer screening. A recent U.S. Preventative Services Task Force recommendation against prostate-specific antigen testing, regardless of age, has added to men's confusion about how to protect themselves from a cancer that hits roughly 240,000 new patients every year and claims 28,000 lives.

Mayo Clinic urologists recommend a personalized approach to determining whether or not a patient should consider PSA screening for prostate cancer. This approach should begin at age 40 and include:

* Individual and family medical history.

* The patient's age, recognizing the age-related increase in cancer risk.

* The patient's ethnic background, noting that African-American men have the highest risk of prostate cancer.

* A discussion of the pros and cons of PSA screening.

* Other medical conditions that can affect PSA score.

Organizations that recommend PSA screening generally encourage the test between ages 40 and 75 and in men with a higher risk of prostate cancer, says Mayo urologist Jeffrey Karnes, M.D.

"It may be a simple test but it's not a simple decision," Dr. Karnes says. "A PSA test is something you should decide after discussing it with your doctor, considering your risk factors and weighing your personal preferences."

Cancer overall is the No. 2 health threat to men. June is Men's Health Month, highlighting health issues of particular concern to men and strategies for prevention and treatment.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Confused about prostate cancer screening? Mayo clinic expert helps explain the latest." ScienceDaily. ScienceDaily, 13 June 2012. <www.sciencedaily.com/releases/2012/06/120613145232.htm>.
Mayo Clinic. (2012, June 13). Confused about prostate cancer screening? Mayo clinic expert helps explain the latest. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/06/120613145232.htm
Mayo Clinic. "Confused about prostate cancer screening? Mayo clinic expert helps explain the latest." ScienceDaily. www.sciencedaily.com/releases/2012/06/120613145232.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins